

## Special Issue

# Health-Related Applications of Natural Molecule Derived Structures

### Message from the Guest Editor

This Special Issue will mainly focus on the role of natural compounds and biomolecules derived from plants, animals, and microorganisms in the application of health-related fields such as the prevention and treatment of infections, diseases, chronic diseases, and so on. Examples of diseases include skin problems, neurodegenerative, cardiovascular, and rheumatic diseases, asthma, diabetes, obesity, and cancers that require a continuous and exhausting treatment process. In the treatment of these maladies, the use of active pharmaceutical ingredients may be limited due to inadequate results, the high toxicity of some drugs, high costs, and difficulty in accessing drugs. Natural compounds such as amino acids, carbohydrates, polyphenolics, peptides, and their polymeric derivatives can have additional activities and contribute to deferring, preventing, and treating the emergence of various diseases. We invite authors in this exciting field to submit their manuscripts (original research, commentaries, short reports, or reviews) to discuss the potential therapeutic effects and mechanisms of action of natural compounds and their derivatives in chronic diseases.

### Guest Editor

Dr. Nurettin Sahiner

1. Department of Bioengineering, U.A. Whitaker College of Engineering, Florida Gulf Coast University, 10501 FGCU Boulevard South, Fort Myers, FL 33965, USA

2. Department of Chemistry, Faculty of Sciences, Canakkale Onsekiz Mart University, Terzioğlu Campus, 17100 Canakkale, Turkey

### Deadline for manuscript submissions

closed (31 August 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/165946](https://mdpi.com/si/165946)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).